Ceryvyn Therapeutics Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CKDXF research report →
Price Chart
About the company
Ceryvyn Therapeutics Ltd is a clinical-stage biopharmaceutical company developing therapies for the rare lung disease lymphangioleiomyomatosis (LAM). Its lead program, CYV-101, is a fusion protein designed to neutralize VEGF-C and VEGF-D, key signaling proteins involved in the disease. The company was formerly known as Opthea Limited.
- CEO
- Jeremy Max Levin Ba Zoology Dphil Mb Bchir
- IPO
- 2011
- Employees
- 33
- HQ
- Hawthorn East, VIC, AU
Get TickerSpark's AI analysis on CKDXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $667.3-97.4%
- Gross Profit
- $667.3+101.0%
- Op Income
- $-7,972,233.1
- Net Income
- $220.51M+235.5%
- EPS
- $0.16+223.1%
- OCF Growth
- +94.6%
- FCF Growth
- +94.6%
- 52W High
- $0.44
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.25
- Beta
- 1.50
- RSI (14)
- 0
- Avg Volume
- 644
No earnings-call transcripts are available for CKDXF yet.
- Free Float
- 85.4%
- Shares Outstanding
- 1.37B
- Float Shares
- 1.17B
Our CKDXF coverage
Recent articles, reports, and earnings notes.
No research on CKDXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CKDXF report →